ArticleDrug safety2021
Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project.
Article in Drug safety, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- The Oral Microbiome and Its Role in Systemic Autoimmune Diseases: A Systematic Review of Big Data Analysis.Frontiers in big data · 2022Pooled it
- Incidence and prevalence of obstructive sleep apnoea and narcolepsy in the UK: a population-based descriptive study.Thorax · 2026Article
- Incidence and prevalence of autoimmune disease in the Swedish National Patient Register.European journal of epidemiology · 2026Article
- Global, regional, and national epidemiology of rheumatoid arthritis among people aged 20-54 years from 1990 to 2021.Scientific reports · 2025Article
- The use of observed-to-expected analyses as a signal detection tool in COVID-19 vaccine safety surveillance: lessons learned from an industry perspective.Frontiers in drug safety and regulation · 2025Review
- Background incidence rates from electronic healthcare databases for vaccine safety monitoring: review of challenges from the COVID-19 vaccination campaign and proposal for best practices.Frontiers in drug safety and regulation · 2025Article
- Trends in mortality related to venous thromboembolism in the European Union, 2012-2020.Internal and emergency medicine · 2024Article
- Comment on "Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project".Drug safety · 2023Article
- Article
- Genetic susceptibility for autoimmune diseases and white blood cell count.Scientific reports · 2023Article
- Osteoimmunology: The effect of autoimmunity on fracture healing and skeletal analysis.Forensic science international. Synergy · 2023Review
- Artificial Intelligence-Based Pharmacovigilance in the Setting of Limited Resources.Drug safety · 2022Review
- Ionic mitigation of CD4Scientific reports · 2022Article
- Risk of Autoimmune Diseases Following Optic Neuritis: A Nationwide Population-Based Cohort Study.Frontiers in medicine · 2022Article
- Factors Influencing Background Incidence Rate Calculation: Systematic Empirical Evaluation Across an International Network of Observational Databases.Frontiers in pharmacology · 2022Article
- Retinoic Acid-Containing Liposomes for the Induction of Antigen-Specific Regulatory T Cells as a Treatment for Autoimmune Diseases.Pharmaceutics · 2021Article
- Real-World Utilization of Target- and Immunotherapies for Lung Cancer: A Scoping Review of Studies Based on Routinely Collected Electronic Healthcare Data.International journal of environmental research and public health · 2021Article
- Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study.BMJ (Clinical research ed.) · 2021Article
- The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety.Vaccine · 2021Article
- Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study.medRxiv : the preprint server for health sciences · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
16 authors at 9 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe public-private ADVANCE collaboration developed and tested a system to generate evidence on vaccine benefits and risks using European electronic healthcare databases. In the safety of vaccines, background incidence rates are key to allow proper monitoring and assessment. The goals of this study were to compute age-, sex-, and calendar-year stratified incidence rates of nine autoimmune diseases in seven European healthcare databases from four countries and to assess validity by comparing with published data.
methodsEvent rates were calculated for the following outcomes: acute disseminated encephalomyelitis, Bell's palsy, Guillain-Barré syndrome, immune thrombocytopenia purpura, Kawasaki disease, optic neuritis, narcolepsy, systemic lupus erythematosus, and transverse myelitis. Cases were identified by diagnosis codes. Participating organizations/databases originated from Denmark, Italy, Spain, and the UK. The source population comprised all persons registered, with at least 1 year of data prior to the study start, or follow-up from birth. Stratified incidence rates were computed per database over the period 2003 to 2014.
resultsBetween 2003 and 2014, 148,947 incident cases of nine autoimmune diseases were identified. Crude incidence rates were highest for Bell's palsy [23.8/100,000 person-years (PYs), 95% confidence interval (CI) 23.6-24.1] and lowest for Kawasaki disease (0.7/100,000 PYs, 95% CI 0.6-0.7). Specific patterns were observed by sex, age, calendar time, and data sources. Rates were comparable with published estimates.
conclusionA range of autoimmune events could be identified in the ADVANCE system. Estimation of rates indicated consistency across selected European healthcare databases, as well as consistency with US published data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.